George Huang

George Huang is a biotechnology analyst at Stansberry & Associates, an
independent equity research firm. His coverage universe includes small- to mid-
cap biotechs with a strong focus in the infectious diseases, metabolic diseases,
autoimmunity, oncology and platform technologies. His research and trading
strategies are featured in two publications (The FDA Report, Phase 1 Investor).
He was the Pollard Scholar and received his PhD in Cellular and Molecular
Medicine from Johns Hopkins University and Bachelor of Science degree in Biology
from University of British Columbia.